

## University of Groningen

### Improving influenza prevention

van Doorn, Eva

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

van Doorn, E. (2018). *Improving influenza prevention: Why universal influenza vaccines are needed*. Rijksuniversiteit Groningen.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# **Improving influenza prevention**

Why universal influenza vaccines are needed

Eva van Doorn

Studies presented in this thesis were supported by funding from the European Union Seventh Framework Program (FP7/2007-2013) under grant agreement number 602012.

Printing of this thesis was financially supported by the University of Groningen, the Graduate School of Science, the Institute for Health Research SHARE, and PRA Health Sciences.



Layout and cover: Douwe Oppewal  
Printing: NetzoDruk Groningen

ISBN (printed version): 978-94-034-0303-8  
ISBN (electronic version): 978-94-034-0302-1

Copyright, 2018, E. van Doorn

No parts of this publication may be reproduced or transmitted in any form or by any means, electronically or mechanically by photocopying, recording, or otherwise, without the written permission of the author, or from the publisher holding the copyright of the published articles.



rijksuniversiteit  
 groningen

# Improving influenza prevention

Why universal influenza vaccines are needed

## Proefschrift

ter verkrijging van de graad van doctor aan de  
Rijksuniversiteit Groningen  
op gezag van de  
rector magnificus prof. dr. E. Sterken  
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

vrijdag 26 januari 2018 om 16.15 uur

door

**Eva van Doorn**

geboren op 7 september 1990  
te Noordoostpolder

**Promotores**

Prof. dr. E. Hak

Prof. dr. A.L.W. Huckriede

**Beoordelingscommissie**

Prof. dr. J.E. McElhanev

Prof. dr. H.G.M. Niesters

Prof. dr. E.P. van Puijenbroek

**Paranimfen**

Annemiek van der Schoot

Ryanne Meijer



# Contents

Chapter 1	General Introduction	9
<b>Part 1</b>	<b>Influenza vaccine effectiveness in the Netherlands</b>	19
Chapter 2	Effectiveness of influenza vaccine in the Netherlands: predominant circulating virus type and vaccine match are important conditions	21
Chapter 3	Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups	31
<b>Part 2</b>	<b>Safety and tolerability evaluation of vaccine adjuvants</b>	51
Chapter 4	Safety and tolerability evaluation of the use of Montanide ISA TM 51 as vaccine adjuvant: A systematic review	53
Chapter 5	Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: Safety and Tolerability	81
<b>Part 3</b>	<b>Clinical evaluation influenza vaccines</b>	111
Chapter 6	National Differences in Requirements for Ethical and Competent Authority Approval For a Multinational Vaccine Trial under the EU Directive 2001/20/EC	113
Chapter 7	Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol	151
Chapter 8	Safety and immunogenicity of M-001 as standalone universal influenza vaccine and as a primer to H5N1 vaccine: Results of a multicenter, randomized, double-blind and controlled Phase IIb trial	167
Chapter 9	General Discussion	185
	Summary	199
	Nederlandse Samenvatting	201
	Acknowledgments / Dankwoord	205
	Curriculum Vitae	209
	List of publications	211
	Research institute SHARE	213

